Publication:
Effectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting.

dc.contributor.authorMete, Bilgul
dc.contributor.authorGunduz, Alper
dc.contributor.authorKaraosmanoglu, Hayat Kumbasar
dc.contributor.authorGumuser, Fatma
dc.contributor.authorBolukcu, Sibel
dc.contributor.authorYildiz, Dilek Sevgi
dc.contributor.authorAydin, Ozlem Altuntas
dc.contributor.authorBilge, Bilgenur
dc.contributor.authorDokmetas, Ilyas
dc.contributor.authorTabak, Fehmi
dc.date.accessioned2023-05-18T21:32:01Z
dc.date.available2023-05-18T21:32:01Z
dc.date.issued2021-11-30T21:00:00Z
dc.description.abstractEfficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (E/C/F/TDF) in treatment-naïve and experienced patients with HIV infection was demonstrated in phase 3 trials. The primary objective of this study was to evaluate effectiveness and safety of E/C/F/TDF in real world settings.
dc.description.abstractRetrospective, observational data collected by the Turkish ACTHIV-IST study group between May 2015 and December 2016 were analysed.
dc.description.abstractA total of 387 patients were prescribed E/C/F/TDF; 210 patients with available data at 6th month were eligible; 91.5% were male, and mean age was 35.2 (SD: 10.8) years; 54.0% of males identified themselves as MSM. Sixty-three percent (133) of the study population were treatment-naïve patients, and 37% (77) were treatment experienced. HIV RNA level was below 100 copies/mL in 78.9% of treatment-naïve patients and 89.9% of treatment experienced patients at month 6. Median increase in CD4 T lymphocyte count was 218 copies/mL in treatment-naïve patients and remained stable or increased in treatment experienced patients. Adverse events were observed in 15% of the patients, and the regimen was discontinued in only six patients.
dc.description.abstractReal world data on the effectiveness and safety of E/C/F/TDF is comparable with the phase 3 trial results Adverse events are uncommon and manageable.
dc.identifier.pubmed35283956
dc.identifier.urihttps://hdl.handle.net/20.500.12645/38321
dc.language.isoen
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsCC0 1.0 Universalen
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/
dc.subjectElvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
dc.subjectHIV
dc.subjecteffectiveness
dc.subjectsafety
dc.titleEffectiveness and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting.
dc.typeArticle
dspace.entity.typePublication
Files